Inspire Medical Systems (INSP)
(Delayed Data from NYSE)
$143.74 USD
+5.92 (4.30%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $143.77 +0.03 (0.02%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth C Momentum D VGM
Inspire Medical Systems (INSP) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$226.40 | $278.00 | $156.00 | 64.27% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Inspire Medical Systems comes to $226.40. The forecasts range from a low of $156.00 to a high of $278.00. The average price target represents an increase of 64.27% from the last closing price of $137.82.
Analyst Price Targets (15)
Broker Rating
Inspire Medical Systems currently has an average brokerage recommendation (ABR) of 1.69 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 1.69 a month ago based on 16 recommendations.
Of the 16 recommendations deriving the current ABR, 10 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 62.5% and 6.25% of all recommendations. A month ago, Strong Buy made up 62.5%, while Buy represented 6.25%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/INSP.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 9 | 10 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 5 | 5 | 5 | 5 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.69 | 1.69 | 1.69 | 1.73 | 1.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/16/2024 | Truist Securities | Richard Newitter | Strong Buy | Strong Buy |
7/12/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Strong Buy | Strong Buy |
6/24/2024 | Lake Street Capital Markets | Frank Takkinen | Strong Buy | Strong Buy |
5/23/2024 | Not Identified | Not Identified | Hold | Hold |
5/8/2024 | Piper Sandler | Adam C Maeder | Strong Buy | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/25/2024 | Not Identified | Not Identified | Hold | Hold |
4/19/2024 | Not Identified | Not Identified | Not Available | Moderate Buy |
3/21/2024 | SVB Securities | Michael Kratky | Hold | Hold |
2/6/2024 | UBS | Danielle Antalffy | Strong Buy | Strong Buy |
2/6/2024 | KeyBanc Capital Markets | Brett Fishbin | Strong Buy | Strong Buy |
12/21/2023 | Robert W. Baird & Co. | David Rescott | Strong Buy | Strong Buy |
12/13/2023 | Wells Fargo Securities | Lawrence H Biegelsen | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.69 |
ABR (Last week) | 1.69 |
# of Recs in ABR | 16 |
Average Target Price | $226.40 |
LT Growth Rate | NA |
Industry | Medical Info Systems |
Industry Rank by ABR | 74 of 252 |
Current Quarter EPS Est: | -0.13 |